These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. Gale JD Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393 [TBL] [Abstract][Full Text] [Related]
3. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents. Thomas RH; Luthin DR Pharmacotherapy; 2015 Jun; 35(6):613-30. PubMed ID: 26016701 [TBL] [Abstract][Full Text] [Related]
5. Current and future therapies for chronic constipation. Tack J Best Pract Res Clin Gastroenterol; 2011 Feb; 25(1):151-8. PubMed ID: 21382586 [TBL] [Abstract][Full Text] [Related]
6. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Tack J; van Outryve M; Beyens G; Kerstens R; Vandeplassche L Gut; 2009 Mar; 58(3):357-65. PubMed ID: 18987031 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic considerations for the current chronic constipation treatments. Müller-Lissner S Expert Opin Drug Metab Toxicol; 2013 Apr; 9(4):391-401. PubMed ID: 23425050 [TBL] [Abstract][Full Text] [Related]
8. New pharmacological treatment options for chronic constipation. Corsetti M; Tack J Expert Opin Pharmacother; 2014 May; 15(7):927-41. PubMed ID: 24661106 [TBL] [Abstract][Full Text] [Related]
9. [Some practical questions on chronic stipsis treatment with prucalopride]. Bellacosa L; Cogliandro R; Cremon C; De Giorgio R; Barbara G; Stanghellini V Minerva Gastroenterol Dietol; 2014 Mar; 60(1):85-99. PubMed ID: 24632771 [TBL] [Abstract][Full Text] [Related]
10. Prucalopride for the treatment of women with chronic constipation in whom standard laxative regimens have failed to provide adequate relief. Pennant M; Orlando R; Barton P; Bayliss S; Routh K; Meads C Health Technol Assess; 2011 May; 15 Suppl 1():43-50. PubMed ID: 21609652 [TBL] [Abstract][Full Text] [Related]
11. Use of prucalopride in adults with chronic idiopathic constipation. Vijayvargiya P; Camilleri M Expert Rev Clin Pharmacol; 2019 Jul; 12(7):579-589. PubMed ID: 31096799 [No Abstract] [Full Text] [Related]
16. Efficacy of linaclotide for patients with chronic constipation. Lembo AJ; Kurtz CB; Macdougall JE; Lavins BJ; Currie MG; Fitch DA; Jeglinski BI; Johnston JM Gastroenterology; 2010 Mar; 138(3):886-95.e1. PubMed ID: 20045700 [TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic constipation: current pharmacologic approaches and future directions. Tack J; Müller-Lissner S Clin Gastroenterol Hepatol; 2009 May; 7(5):502-8; quiz 496. PubMed ID: 19138759 [TBL] [Abstract][Full Text] [Related]
18. The impact of laxative use upon symptoms in patients with proven slow transit constipation. Dinning PG; Hunt L; Lubowski DZ; Kalantar JS; Cook IJ; Jones MP BMC Gastroenterol; 2011 Nov; 11():121. PubMed ID: 22073923 [TBL] [Abstract][Full Text] [Related]
19. Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome. Chamberlain SM; Rao SS Expert Opin Drug Saf; 2012 Sep; 11(5):841-50. PubMed ID: 22834474 [TBL] [Abstract][Full Text] [Related]
20. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study. Quigley EM; Vandeplassche L; Kerstens R; Ausma J Aliment Pharmacol Ther; 2009 Feb; 29(3):315-28. PubMed ID: 19035970 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]